about
The risks of overlooking the diagnosis of secreting pituitary adenomasTreatment for prolactinomas and hyperprolactinaemia: a lifetime approach.Management of macroprolactinomas.Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study.Mutant prolactin receptor and familial hyperprolactinemia.HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study.Imaging of pediatric pituitary endocrinopathiesSuccessful treatment of a prolactinoma with the antipsychotic drug aripiprazole.Prolactinoma: A Massive Effect on Bone Mineral Density in a Young Patient.Management of Cushing disease.Radiotherapy for prolactin-secreting pituitary tumors.Temozolomide in the management of dopamine agonist-resistant prolactinomas.Comprehensive review of stereotactic radiosurgery for medically and surgically refractory pituitary adenomas.Macroprolactinoma: a diagnostic and therapeutic update.Medical management of Cushing's disease.Surgical treatment of microprolactinomas: pros.Single-centre experience of stereotactic radiosurgery and fractionated stereotactic radiotherapy for prolactinomas with the linear accelerator.The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS).Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.Preoperative Stratification of Transsphenoidal Pituitary Surgery Patients Based on Surgical Urgency.The safety of treatments for prolactinomas.Is there a role for early chemotherapy in the management of pituitary adenomas?Management of prolactinomas: a survey of physicians from the Middle East and North Africa.The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells.Rapid improvement in visual field with cabergoline in suprasellar tumor in a young adult: Clinical dilemma solved and surgery averted.High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas.BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: a pilot study in a Chinese cohort.Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression.Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience.Significance of surgical management for cystic prolactinoma.Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study.Management of prolactinoma: a survey of endocrinologists in China
P2860
Q28076665-BA15A77C-2D96-4D92-B2C2-914B04C8FF0BQ33721266-ABCB3FC8-1AB1-4B7F-9060-FC531F889416Q33792371-A57329EF-28C0-4EF5-A636-78071B1F7E4DQ33943570-963B7215-29EA-40F7-8B1B-959475EEA20CQ34402577-99F59D03-0647-4456-904D-BC64F602F363Q34942996-CEB66ACC-0AB5-4B33-B87B-80435D8A3F1FQ35048001-1BE2E589-9DE7-4EA5-AD8F-D134720C1297Q35546563-B29E3C44-7CC0-4D46-BC02-874487BEB0ACQ36331597-1FAEE897-4196-44DA-8F0F-D50B34557854Q36981276-47F5205C-3EAE-4334-A480-5E873637AEF7Q37092869-72E9A0CD-A5EE-4F29-9316-A69C90D7A5A0Q37837501-D69A18AC-B1D1-46BF-A01C-A4AC3D6CDCC7Q37938974-5854FA08-331C-4541-9F8A-4CCA807FC925Q37988909-DEE8CA35-FED5-4221-8D67-2A860DE702C0Q38028958-C09E06C4-68EA-499A-BF56-571E2D621B30Q38074909-7D2F8B47-DEDC-4798-98CB-29EEC84EB7DBQ38154515-9A99ED17-03CC-4338-8969-41605A13B52BQ38211820-6579BCFA-88C4-439B-B30F-42233F6BDF79Q38269620-FF14FD32-91BB-496B-88B2-43800294FAC2Q38406655-93B35884-25EB-4A62-B100-BE518DC2D122Q38435312-580365C2-1829-495D-BBFE-1B905F30FC53Q38682306-AF28DE48-8208-4BFD-BD75-2EE1EEDDB2B0Q38726058-047A2A9A-B866-48AA-94D9-4EA8E90A0234Q38815400-BFE05459-92D3-459B-8919-0FD7FD4FC7B8Q38906545-8804C098-07F5-44DA-B788-FDD17D32FADBQ39014107-AAD57D8E-1FC2-420F-8274-F6059D4DD8DFQ42155577-65A828D7-AB34-4F41-8A11-668724572662Q43903587-A63F5A49-45F2-4041-94BD-2302B6DAB424Q44383758-5D7F462D-AE8E-47FC-92F9-A95E04C9F3E6Q44595701-4ACD4A2C-78FA-483A-9E74-5F9A938EDEA4Q47266565-7A2FCCDA-CA1C-4297-B33C-FEFA179C4DE9Q48967667-4C1DF3DC-6C7E-4970-8D78-E4FAED7F5B83Q50917186-D9692E93-7698-4FC0-97C4-A000E013CA64Q57818917-BBD788D9-6D18-4372-A588-99FB91203B5A
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical practice. Prolactinomas.
@en
Clinical practice. Prolactinomas.
@nl
type
label
Clinical practice. Prolactinomas.
@en
Clinical practice. Prolactinomas.
@nl
prefLabel
Clinical practice. Prolactinomas.
@en
Clinical practice. Prolactinomas.
@nl
P356
P1476
Clinical practice. Prolactinomas.
@en
P304
P356
10.1056/NEJMCP0912025
P407
P577
2010-04-01T00:00:00Z